StockNews.com cut shares of Aurinia Pharmaceuticals (NASDAQ:AUPH - Free Report) TSE: AUP from a strong-buy rating to a buy rating in a research report report published on Wednesday.
Aurinia Pharmaceuticals Price Performance
AUPH traded up $0.10 during trading on Wednesday, reaching $7.93. 1,298,612 shares of the stock were exchanged, compared to its average volume of 1,259,248. The business's 50 day moving average price is $8.33 and its two-hundred day moving average price is $7.68. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -52.83 and a beta of 1.22. Aurinia Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $10.67.
Hedge Funds Weigh In On Aurinia Pharmaceuticals
Institutional investors have recently made changes to their positions in the stock. SBI Securities Co. Ltd. acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $25,000. GF Fund Management CO. LTD. acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $27,000. Tower Research Capital LLC TRC raised its holdings in shares of Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $31,000. Finally, Natixis acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $49,000. 36.83% of the stock is owned by institutional investors and hedge funds.
About Aurinia Pharmaceuticals
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Stories
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
